Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines – a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits
Susan P. Felter(Procter & Gamble (United States)), Joel P. Bercu(Eli Lilly (United States)), Matthew Schmitz(Takeda (United States)), Alisa Vespa(Health Canada), David J. Ponting(University of Leeds), Robert Thomas, Andreas Zeller(Roche (Switzerland)), Timothy J. McGovern(Center for Drug Evaluation and Research), Bodo Haas(Federal Institute for Drugs and Medical Devices), Anthony M Lynch(Age UK), Ashley M Mudd(Procter & Gamble (United States)), Raechel Puglisi(Health and Environmental Sciences Institute), Yi Yan Yang(Jiangsu University), Roland Froetschl(Federal Institute for Drugs and Medical Devices), Angela White(GlaxoSmithKline (United Kingdom))
Cited by 5
Related Papers
The effects of polymeric nanostructure shape on drug delivery
|Advanced Drug Delivery Reviews|2011|507
A macromolecular approach to eradicate multidrug resistant bacterial infections while mitigating drug resistance onset
|Nature Communications|2018|330
The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2014|156
The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny
|Organic Process Research & Development|2023|78
Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay
|Environmental and Molecular Mutagenesis|2017|74